Beam stock forecast.
Analyst Forecast. According to 2 analysts, the average rating for BEAT stock is "Strong Buy." The 12-month stock price forecast is $6.78, which is an increase of 361.22% from the latest price.
The average Beam Therapeutics stock price prediction forecasts a potential upside of 52.06% from the current BEAM share price of $27.95. What is BEAM's forecast return on equity (ROE) for 2023-2026? ( NASDAQ : BEAM ) forecast ROE is N/A , which is considered weak .(See Tritium stock forecast on TipRanks) Beam Global . Beam Global, the second EV charging stock we’re looking at, provides a range of power products for use in a variety of charging and battery ...NTLA Stock 12 Months Forecast. Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $78.65 with a high forecast of $136.00 and a low forecast of $31.00. The average price target represents a 151.68% change from the last price of $31.25.In the field of construction, the use of steel beams is vital for providing structural support and stability to buildings. When it comes to steel beams, using standardized sizes has numerous benefits.
Dec 1, 2023 · A high-level overview of Beam Therapeutics Inc. (BEAM) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
According to 4 analyst offering 12-month price targets in the last 3 months, Beam Therapeutics has an average price target of $70.25 with a high of $105.00 and a low of $37.00. Below is a summary ...BEEM Stock 12 Months Forecast. $24.00. (228.09% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Beam Global in the last 3 months. The average price target is $24.00 with a high forecast of $40.00 and a low forecast of $12.00. The average price target represents a 228.09% change from the last price of $7.32.
Find real-time ROKU - Roku Inc stock quotes, company profile, news and forecasts from CNN Business.Stock Price Forecast. The 20 analysts offering 12-month price forecasts for Nintendo Co Ltd have a median target of 46.72, with a high estimate of 59.00 and a low estimate of 31.78. The median ...Lockheed Martin (NYSE:LMT) pays an annual dividend of $12.00 per share and currently has a dividend yield of 2.69%. The company has been increasing its dividend for 21 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 43.84%.Beam Therapeutics last released its earnings results on November 8th, 2023. The reported ($1.22) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.11. The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $17.09 million. Its revenue was up 8.9% on a year-over-year basis.Dec 1, 2023 · Scores. BEAM has an Altman Z-Score of 1.39 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy. Altman Z-Score. 1.39. Piotroski F-Score. 2. Detailed statistics for Beam Therapeutics Inc. (BEAM) stock, including valuation metrics, financial numbers, share information and more.
Nov 18, 2023 · Future criteria checks 1/6. Beam Therapeutics's earnings are forecast to decline at 11.2% per annum while its annual revenue is expected to grow at 12.2% per year. EPS is expected to decline by 3.5% per annum. Return on equity is forecast to be -82.9% in 3 years.
Nov 29, 2023 · The Beam Global stock price fell by -1.95% on the last day (Wednesday, 29th Nov 2023) from $6.14 to $6.02. During the last trading day the stock fluctuated 9.27% from a day low at $6.01 to a day high of $6.57. The price has fallen in 7 of the last 10 days and is down by -17.53% for this period. Volume fell on the last day along with the stock ...
Meanwhile, Cathie Wood has been adding more BEAM shares to the ARKG ETF. During January, she purchased 163,838 shares. The ETF now hold 2,126,439 shares in total, currently worth ~$92.4 million ...Find the latest Ion Beam Applications SA (IBAB.BR) stock quote, history, news and other vital information to help you with your stock trading and investing.According to analyst projections, BEAM’s forecast low is $19.00 with $95.00 as the target high. To hit the forecast high, the stock’s price needs a -219.33% plunge from its current level, while the stock would need to tank 36.13% for it to hit the projected low. Beam Therapeutics Inc (BEAM) estimates and forecastsBeam Therapeutics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. ... We provide commentary based on historical data and analyst forecasts ...BEAM : Suntory Holdings Completes Acquisition of Beam Inc. 2014: BU BEAM : Jim Beam To Host "Distillery Days" In Clermont 2014: PR Beam : Announces Intention to Delist and Deregister Common Stock, 8 5/8% Debentures Due 2021 and 7 …
BEST Inc. (NYSE:BEST) announced its earnings results on Monday, August, 16th. The company reported ($22.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($14.60) by $7.60. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.26 billion.Find real-time BMRN - Biomarin Pharmaceutical Inc stock quotes, company profile, news and forecasts from CNN Business.... price action for Beam Therapeutics (BEAM) ... In the historical earnings table above, you can find BEAM historical earnings dates and the historical stock price ...Lockheed Martin (NYSE:LMT) pays an annual dividend of $12.00 per share and currently has a dividend yield of 2.69%. The company has been increasing its dividend for 21 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 43.84%.See the latest Beam Therapeutics Inc stock price (BEAM:XNAS), related news, valuation, dividends and more to help you make your investing decisions. This is where a guiding hand from Wall Street’s pros comes in handy. The stock experts at banking giant Wells Fargo have identified two names whose share price is down over 50% this year ...
Track Beam Therapeutics Inc (BEAM) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
Average 51.83 75.87% Upside Low 19.00 -35.53% Downside High 95.00 222.36% Upside Broker Rating Beam Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.86 on a scale of...Infibeam Avenues Ltd., incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 5,667.88 Crore) operating in Services sector. Infibeam Avenues Ltd. key Products/Revenue Segments include Software Development Charges & Other Services for the year ending 31-Mar-2023.For the ...Stock Forecast for the Price of an Beam Therapeutics Share in Feb 2025. In February 2025, analysts believe the stock price will be $21.97. An increase of 15.15% compared to the previous month's estimate.AUPH Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $14.20 with a high forecast of $15.00 and a low forecast of $13.00. The average price target represents a 71.29% change from the last price of $8.29.Beam Global Stock Forecast and Price Target. In recent months, notable analysts have provided yearlong price targets for Beam Global, with the average target coming in at $18.00. If it were to be achieved, this would result in a potential upside of approximately 222 percent from the most recent closing price in November, 2023.Dec 1, 2023 · John Evans. Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the ... Beam Therapeutics Inc. 27.50. Delayed Data. As of Nov 17. +2.71 / +10.93%. Today’s Change. 16.95. Today ||| 52-Week Range. 51.60.Earnings vs Market: BEEM is forecast to become profitable over the next 3 years, which is considered above average market growth. High Growth Earnings: BEEM is expected to become profitable in the next 3 years. Revenue vs Market: BEEM's revenue (24.5% per year) is forecast to grow faster than the US market (7.7% per year).NEW YORK, February 15, 2023--Beam Suntory, a world leader in premium spirits, today announced 2022 full year results, with net sales up 10.5% year on year, representing 24% growth versus the pre ...
Lumber increased 29.16 USD/1000 board feet or 5.87% since the beginning of 2023, according to trading on a contract for difference (CFD) that tracks the benchmark market for this commodity. Lumber - values, historical data, forecasts and news - updated on December of 2023.
Get the latest Infibeam Avenues Ltd (INFIBEAM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing ... The stock of Beam Therapeutics (BEAM 5.31%), a clinical-stage genetic base-editing company, has shed 48% of its value relative to its 52-week high in recent weeks.3 Wall Street research analysts have issued 12-month price targets for Beam Global's shares. Their BEEM share price targets range from $25.00 to $25.00. On average, they anticipate the company's stock price to reach $25.00 in the next year. This suggests a possible upside of 315.3% from the stock's current price.Chronic organ damage is the leading cause of death in adults with SCD. Beam is advancing multiple base editing programs for sickle cell disease, led by Beam-101, an ex vivo cell therapy in which cells are collected from a patient, edited, and then infused back into the patient. To create space for the edited cells to take hold in the bone ...Beam Therapeutics Inc. 27.50. Delayed Data. As of Nov 17. +2.71 / +10.93%. Today’s Change. 16.95. Today ||| 52-Week Range. 51.60.Find real-time DDOG - Datadog Inc stock quotes, company profile, news and forecasts from CNN Business. ... EPS forecast (this quarter) $0.32: Annual revenue (last year) $1.7B: Annual profit (last ...Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...Get the latest Lumber price (LBR) as well as the latest futures prices and other commodity market news at Nasdaq.Lumber increased 29.16 USD/1000 board feet or 5.87% since the beginning of 2023, according to trading on a contract for difference (CFD) that tracks the benchmark market for this commodity. Lumber - values, historical data, forecasts and news - updated on December of 2023.This is where a guiding hand from Wall Street’s pros comes in handy. The stock experts at banking giant Wells Fargo have identified two names whose share price is down over 50% this year ...BEAM Stock 12 Months Forecast. $43.44. (58.25% Upside) Based on 11 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $43.44 with a high forecast of $75.00 and a low forecast of $19.00. The average price target represents a 58.25% change from the last price of $27.45. The average Beam Therapeutics stock forecast 2024 represents a 80.7% increase from the last price of $28.5900001525879. For Beam Therapeutics stock forecast for 2026, 12 predictions are offered for each month of 2026 with average Beam Therapeutics stock forecast of $75.12, a high forecast of $83.03, and a low forecast of $61.46.
Find real-time AVGO - Broadcom Inc stock quotes, company profile, news and forecasts from CNN Business. ... EPS forecast (this quarter) $10.95: Annual revenue (last year) $33.2B: Annual profit ...Infibeam Avenue Share Price: Find the latest news on Infibeam Avenue Stock Price. Get all the information on Infibeam Avenue with historic price charts for ...14,305.03 +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Beam Therapeutics Inc. (BEAM) NasdaqGS - NasdaqGS Real Time Price.... AADI Stock 12 Months Forecast. $33.00. (599.15% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Aadi Bioscience in the last 3 months. The average price target is $33.00 with a high forecast of $36.00 and a low forecast of $30.00. The average price target represents a 599.15% change from the last price of $4.72.Instagram:https://instagram. value of 1921 morgan dollarsell my xbox 360neggconventional loan lenders Tritium shares are priced at $6.34 and their average price target of $14.40 implies an upside potential of ~127%. ( See Tritium stock forecast on TipRanks) Beam Global, the second EV charging ...BEEM Stock 12 Months Forecast. $24.00. (228.09% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Beam Global in the last 3 months. The average price target is $24.00 with a high forecast of $40.00 and a low forecast of $12.00. The average price target represents a 228.09% change from the last price of $7.32. llc canadabest swing traders Well, it was only a matter of time. Advertising giant Facebook announced Wednesday that they’re going to begin testing advertising inside virtual reality titles on its Oculus platform soon. The first roll-out is limited enough, with Faceboo...Apple Inc () Stock Market info Recommendations: Buy or sell Apple stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Apple share forecasts, stock quote and buy / sell signals below.According to present data Apple's AAPL shares and potentially its market environment have been in a bullish cycle in the last 12 … which quarters are worth a lot of money BEAM Stock 12 Months Forecast. $43.44. (58.25% Upside) Based on 11 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $43.44 with a high forecast of $75.00 and a low forecast of $19.00. The average price target represents a 58.25% change from the last price of $27.45. According to analyst projections, BEAM’s forecast low is $19.00 with $95.00 as the target high. To hit the forecast high, the stock’s price needs a -219.33% plunge from its current level, while the stock would need to tank 36.13% for it to hit the projected low. Beam Therapeutics Inc (BEAM) estimates and forecastsFind the latest Ion Beam Applications SA (IBAB.BR) stock quote, history, news and other vital information to help you with your stock trading and investing.